Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FROVA vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Acute treatment of migraine with or without aura in adults
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5 mg orally once daily; maximum 5 mg/day.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life is 26 hours. This prolonged half-life supports once-daily dosing and provides sustained headache relief.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Hepatic via CYP1A2; primary metabolite is 5-hydroxyfrovatriptan.
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Primarily hepatic metabolism followed by renal and fecal elimination. Approximately 62% of the dose is recovered in urine (mainly as metabolites, <10% unchanged) and 32% in feces.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
Approximately 15% bound to plasma proteins (primarily albumin).
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
Volume of distribution (Vd) is approximately 2.4 L/kg, indicating extensive tissue distribution.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral bioavailability is approximately 30% due to first-pass metabolism.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No adjustment required for GFR ≥30 m L/min; use not recommended for GFR <30 m L/min.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Contraindicated in severe hepatic impairment (Child-Pugh C); use with caution in moderate impairment (Child-Pugh B) at reduced dose (2.5 mg every other day).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Not approved for use in pediatric patients; safety and efficacy not established.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
No specific dose adjustment, but monitor for increased sensitivity and renal function due to age-related decline.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Do not use in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular conditions.
None
Risk of myocardial ischemia, cerebral hemorrhage, cardiac arrhythmias; serotonin syndrome with concomitant serotonergic drugs; medication overuse headache; severe hepatic impairment.
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Ischemic heart disease, coronary artery vasospasm, history of stroke/TIA, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, recent MAOI use, hypersensitivity.
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
No significant food interactions. Grapefruit juice does not affect frovatriptan metabolism. Avoid alcohol during migraine attacks as it may worsen headache or increase drowsiness.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal abnormalities at maternal toxic doses. In humans, there is no adequate data; however, triptans as a class may increase risk of preterm delivery, low birth weight, and possibly orofacial clefts when used in the first trimester. Use during first trimester: Risk category not formally assigned but should be avoided. Second and third trimesters: Avoid due to potential for uterine contractions and reduced placental perfusion. Labor and delivery: Contraindicated as it may cause uterine hypertonicity and fetal distress.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Frovatriptan is excreted into breast milk in low amounts; the M/P ratio is approximately 2.6:1 (milk to plasma ratio). The relative infant dose is estimated at 1.5-3.5% of the maternal weight-adjusted dose. While adverse effects in breastfed infants have not been reported, caution is advised due to potential for vasoconstriction and gastrointestinal disturbances. Consider pumping and discarding milk for 24 hours after dose.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, hepatic metabolism alterations) may reduce frovatriptan exposure. However, due to contraindication and lack of safety data, no adjusted dosing is recommended. Use in pregnancy is not advised; alternative medications with better safety profiles (e.g., sumatriptan) should be considered if triptan therapy is necessary.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
Frovatriptan has the longest half-life (~26 hours) among triptans, which may be beneficial for patients with prolonged migraine attacks or frequent recurrence. Onset of action is slower (~2-4 hours) compared to sumatriptan. Use with caution in patients with cardiovascular risk factors due to vasoconstrictive effects. Contraindicated within 24 hours of other triptans or ergotamine-containing medications.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take FROVA at the first sign of a migraine headache, but it can be taken any time during an attack.,Do not exceed one tablet (2.5 mg) in a 24-hour period; if headache returns, repeat dose after at least 2 hours.,Do not take within 24 hours of another triptan or ergotamine-type medication.,Common side effects include dizziness, fatigue, tingling, and flushing. Report chest tightness, palpitations, or shortness of breath immediately.,Seek emergency care if headache worsens or is accompanied by stiff neck, fever, or vision changes.,Inform your doctor if you have heart disease, high blood pressure, liver disease, or are pregnant or breastfeeding.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FROVA vs ADALAT, answered by our medical review team.
FROVA is a Antimigraine (triptan) that works by Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FROVA and ADALAT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FROVA is: 2.5 mg orally once daily; maximum 5 mg/day.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FROVA and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FROVA is classified as Category C. Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.